UPMC Salvator Mundi: CME Course on Prostatic Hypertrophy and Prostate Cancer
On May 17, 2025, UPMC Salvator Mundi International Hospital will host the CME course, “Prostatic Hypertrophy and Prostate Cancer: Putting the Patient Back at the Center,” focusing on the importance of a multidisciplinary approach in the treatment of prostatic hypertrophy.
The course is scientifically coordinated by Professor Pierluigi Bove, head of the Robotic and Minimally Invasive Urology Department of Policlinico Tor Vergata, and Dr. Matteo Vittori, staff physician of the Urology Unit of San Carlo di Nancy Hospital in Rome. Both experts have extensive experience in the field of urology.
This free course, accredited for 6 CME credits, is open to a maximum of 60 medical doctors, particularly general practitioners, radiotherapists, oncologists, and urologists.
Benign Prostatic Hypertrophy (BPH) and Prostate Cancer
The incidence of Benign Prostatic Hypertrophy (BPH) increases by approximately 10% per decade after the age of 50, affecting up to 80% of men aged between 70 and 80. In addition to urinary symptoms, which can significantly impact the quality of life, BPH can lead to irreversible damage to detrusor muscle contractility. While medications and surgery are effective treatment options, timely intervention is essential to prevent potential complications.
Prostate cancer is currently the second most frequently diagnosed cancer in men, with approximately 1.4 million new cases globally each year. The introduction of the PSA test has significantly improved early detection, but it has also sparked debate about the risk of overtreatment. While curative treatments are effective, they can result in significant side effects, making conservative strategies a viable option for patients with low-risk forms of the disease.
Clinical decisions regarding screening, diagnosis, and treatment must take into account life expectancy, overall health status, frailty, comorbidities, and age. Generally, a life expectancy of over 10 years is considered a threshold for benefiting from localized treatment. However, older patients with high-risk forms should not be overlooked, as 15-year prostate cancer-specific mortality can exceed 35% in such cases.
Course Objectives
The course aims to raise awareness among healthcare professionals about the need for increasingly effective and close multidisciplinary collaboration, with two key goals:
- reducing the risk of overtreatment in patients with low-risk conditions,
- optimizing diagnostic and therapeutic programs for patients with high-risk oncological forms.
Through interaction among specialists from various disciplines, the event seeks to promote an integrated approach that places the patient and their individual clinical condition at the center of care.
CME Provider and Organizing Secretariat
Ellesseeventi
Via Francesco Ferrara 40, 00191 Rome
Tel: +39 0636382006
Email: info@ellesseeventi.it
For more information and to register, visit the event page.